Biogen

BIIB

Market cap $26.3B

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy's novel and proprietary AntiClastic™ ASO Platform. Through this collaboration, Biogen will apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligibl.

Management aims to book a $34 million charge in the quarter. This is due to loftier anticipated spend on items such as milestone payments and research and development activities.

Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.

BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Apellis will receive $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contin.

If all goes as planned, it'll soon be the owner of Apellis Pharmaceuticals. The company's asset-to-be has two commercialized medicines on the market based on the same active ingredient.

Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apellis shareholders will also receive a nontransferable contingent value right (CVR) worth up to $4 per share if certain global sales milestones for SYFOVRE are achieved.